Bioceres Crop Solutions (BIOX) Q1 2026 earnings summary

Executive summary

• Revenue declined 17% year-over-year to $77.5 million, reflecting a strategic shift away from low-margin, working-capital-intensive sales and a transition in the seed business.

• Gross margin expanded to 47%, up from 40%, driven by a more profitable product mix and cost discipline.

• Adjusted EBITDA rose 61% year-over-year to $13.6 million, supported by significant cost reductions.

• Operating profit increased to $7.1 million, a 200% year-over-year rise, but net loss widened to $7.5 million.

• Management emphasized progress on margin expansion, working capital reduction, and cost control.

Financial highlights

• Gross profit was $36.2 million, a 3% decrease year-over-year, with gross margin at 47%.

• Operating expenses decreased by $5.9 million year-over-year, with SG&A falling to $23.1 million.

• Net financial debt was $225.9 million, stable versus the prior quarter.

• Total financial debt decreased to $242.5 million as of September 30, 2025.

• Working capital reduced by 20% year-over-year, maintaining a target of approximately four months of sales.

Outlook and guidance

• Revenue decline in seeds expected to continue for at least two more quarters as inventory sell-off comparisons persist.

• Management remains focused on margin expansion, cost reduction, and disciplined capital allocation.

• Early signs of market normalization in Argentina, though recovery is gradual.

• Revenue performance impacted by timing of sales in Latin America, especially Uruguay.